Sodium-glucose cotransport inhibitors: Mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 8, 2015, Pages 1272-1276

  Vlotides, George ^a   Mertens, Peter R ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

diabetes; gliflozines; glucosuria; inflammation; nephropathy

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; INSULIN; METFORMIN; PHLORIZIN; PIOGLITAZONE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT;

BLADDER CANCER; CHRONIC KIDNEY DISEASE; DEHYDRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; GENITAL TRACT INFECTION; GLUCOSE METABOLISM; GLUCOSURIA; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; INHIBITION KINETICS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84939611882     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu299     Document Type: Review

References (36)

1. Abdul-Ghani MA, Defronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport. J Intern Med 2014; 276: 352-363
2. Malla P, Kumar R, Mahapatra MK et al. Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure. Med Res Rev 2014; 8: 1013-1027
3. Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 2000; 23: 237-246
4. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3-9
5. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-531
6. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794
7. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447: 510-518
8. Kanai Y, Lee WS, You G et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404
9. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 1997; 8: 943-948
10. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-129
11. Kleinzellerr AKA. Membrane Transport and Metabolism. Praha: Publishing House of the Czechoslovak Academy of Sciences, 1961, p. 608
12. Barry RJ, Dikstein S, Matthews J et al. Electrical potentials associated with intestinal sugar transfer. J Physiol 1964; 171: 316-338
13. Turner RJ, Moran A. Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. JMembr Biol 1982; 70: 37-45
14. Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 1982; 242: F406-F414
15. Hediger MA, Coady MJ, Ikeda TS et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987; 330: 379-381
16. Hediger MA, Turk E, Wright EM. Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters. Proc Natl Acad Sci USA 1989; 86: 5748-5752
17. Wells RG, Pajor AM, Kanai Y et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 1992; 263(3 Pt 2): F459-F465
18. Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 1933; 12: 1083-1090
19. Vick H, Diedrich DF, Baumann K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol 1973; 224: 552-557
20. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800
21. Dobbins RL, O'Connor-Semmes R, Kapur A et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012; 14: 15-22
22. Bickel M, Brummerhop H, FrickWet al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008; 58: 574-580
23. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883
24. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig 2014; 5: 265-275
25. Terami N, Ogawa D, Tachibana H et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014; 9: e100777
26. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508
27. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs 2013; 73: 979-988
28. Balakumar P, Sundram K, Dhanaraj SA. Dapagliflozin: glucuretic action and beyond. Pharmacol Res 2014; 82C: 34-39
29. Zhang L, Feng Y, List J et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516
30. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90
31. Sarashina A, Koiwai K, Seman LJ et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2013; 28: 213-219
32. Rosenstock J, Seman LJ, Jelaska A et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-1160
33. Veltkamp SA, Kadokura T, Krauwinkel WJ et al. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011; 31: 839-851
34. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med 2013; 159: 262-274
35. Kohan DE, Fioretto P, Tang W et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-971
36. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-1027